Vertex licenses blood disorder gene therapy from CRISPR Therapeutics – FierceBiotech
FierceBiotech |
Vertex licenses blood disorder gene therapy from CRISPR Therapeutics
FierceBiotech Vertex and CRISPR Therapeutics expect to begin clinical trials of a gene-editing treatment for beta-thalassemia and sickle cell disease in 2018. ShareFacebook Twitter LinkedIn Email Print. Vertex Pharmaceuticals bet big on gene editing in 2015, when it … Vertex, CRISPR Therapeutics To Co-develop And Co-commercialize CTX001 |
